Minimal residual diseases detection in childhood cancers
Project leader: Prof Ellen van der Schoot MD PhD
The prognosis of cancers in childhood is often better than in adults, but yet many children do not survive. To recognize children who might benefit from other therapeutic strategies, in collaboration with GA Tytgat, HN Caron and R Versteeg (AMC/ EKZ, Amsterdam), V de Haas (SKION), JJM van Dongen and VHJ van der Velden (Erasmus MC), we develop and evaluate assays for the detection of minimal residual disease in childhood cancers. We demonstrated that hyper-methylated RASSF1a can be used as a DNA marker for the detection of minimal residual disease for neuroblastoma.
- Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, Tytgat GA, van der Schoot CE. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma. Clin Cancer Res 2012; 18(3):808-14.
- Waanders E, van der Velden VH, van der Schoot CE, van Leeuwen FN, van Reijmersdal SV, de Haas V, Veerman AJ, van Kessel AG, Hoogerbrugge PM, Kuiper RP, van Dongen JJ. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 2011; 25(2):254-8.